LIVIVO - Search results -

Search results

Result 1 - 10 of total 61

Search options

Article ; Online: Comment on Tanmoy et al. CRISPR-Cas Diversity in Clinical

Fabre, Laetitia / Njamkepo, Elisabeth / Weill, François-Xavier

2021 Volume 12, Issue 8

Abstract: Tanmoy et al. [ ... ]. ...

Abstract	Tanmoy et al. [...].
MeSH term(s)	CRISPR-Cas Systems ; Salmonella typhi/genetics
Language	English
Publishing date	2021-07-28
Publishing country	Switzerland
Document type	Journal Article ; Comment
ZDB-ID	2527218-4
ISSN	2073-4425 ; 2073-4425
ISSN (online)	2073-4425
ISSN	2073-4425
DOI	10.3390/genes12081142
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Article ; Online: ShigaPass: an

Yassine, Iman / Hansen, Elisabeth E / Lefèvre, Sophie / Ruckly, Corinne / Carle, Isabelle / Lejay-Collin, Monique / Fabre, Laetitia / Rafei, Rayane / Pardos de la Gandara, Maria / Daboussi, Fouad / Shahin, Ahmad / Weill, François-Xavier

Microbial genomics

2023 Volume 9, Issue 3

Abstract: ... ...

Abstract	Shigella
MeSH term(s)	Serogroup ; Multilocus Sequence Typing ; O Antigens/genetics ; Shigella/genetics ; Serotyping/methods
Chemical Substances	O Antigens
Language	English
Publishing date	2023-03-23
Publishing country	England
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	2835258-0
ISSN	2057-5858 ; 2057-5858
ISSN (online)	2057-5858
ISSN	2057-5858
DOI	10.1099/mgen.0.000961
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Prognostic value of forward flow indices in primary mitral regurgitation due to mitral valve prolapse.

Petolat, Elisabeth / Theron, Alexis / Resseguier, Noemie / Fabre, Cyprien / Norscini, Giulia / Badaoui, Rita / Habib, Gilbert / Collart, Frederic / Zaffran, Stéphane / Porto, Alizée / Avierinos, Jean-François

Frontiers in cardiovascular medicine

2023 Volume 10, Page(s) 1076708

Abstract: Background: Degenerative mitral regurgitation (DMR) due to mitral valve prolapse (MVP) is a common valve disease associated with significant morbidity and mortality. Timing for surgery is debated for asymptomatic patients without Class I indication, ... ...

Abstract	Background: Degenerative mitral regurgitation (DMR) due to mitral valve prolapse (MVP) is a common valve disease associated with significant morbidity and mortality. Timing for surgery is debated for asymptomatic patients without Class I indication, prompting the search for novel parameters of early left ventricular (LV) systolic dysfunction. Aims: To evaluate the prognostic impact of preoperative forward flow indices on the occurrence of post-operative LV systolic dysfunction. Methods: We retrospectively included all consecutive patients with severe DMR due to MVP who underwent mitral valve repair between 2014 and 2019. LVOT Results: A total of 198 patients were included: 154 patients (78%) were asymptomatic, and 46 patients (23%) had hypertension. The mean preoperative LVEF was 69 ± 9%. 35 patients (18%) had LVEF ≤ 60%, and 61 patients (31%) had LVESD ≥40 mm. The mean post-operative LVEF was 59 ± 9%, and 21 patients (11%) had post-operative LVEF<50%. Based on multivariable analysis, LVOT Conclusion: LVOT
Language	English
Publishing date	2023-02-23
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2781496-8
ISSN	2297-055X
ISSN	2297-055X
DOI	10.3389/fcvm.2023.1076708
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Rapid emergence of extensively drug-resistant Shigella sonnei in France.

Lefèvre, Sophie / Njamkepo, Elisabeth / Feldman, Sarah / Ruckly, Corinne / Carle, Isabelle / Lejay-Collin, Monique / Fabre, Laëtitia / Yassine, Iman / Frézal, Lise / Pardos de la Gandara, Maria / Fontanet, Arnaud / Weill, François-Xavier

Nature communications

2023 Volume 14, Issue 1, Page(s) 462

Abstract: Shigella sonnei, the main cause of bacillary dysentery in high-income countries, has become increasingly resistant to antibiotics. We monitored the antimicrobial susceptibility of 7121 S. sonnei isolates collected in France between 2005 and 2021. We ... ...

Abstract	Shigella sonnei, the main cause of bacillary dysentery in high-income countries, has become increasingly resistant to antibiotics. We monitored the antimicrobial susceptibility of 7121 S. sonnei isolates collected in France between 2005 and 2021. We detected a dramatic increase in the proportion of isolates simultaneously resistant to ciprofloxacin (CIP), third-generation cephalosporins (3GCs) and azithromycin (AZM) from 2015. Our genomic analysis of 164 such extensively drug-resistant (XDR) isolates identified 13 different clusters within CIP-resistant sublineage 3.6.1, which was selected in South Asia ∼15 years ago. AZM resistance was subsequently acquired, principally through IncFII (pKSR100-like) plasmids. The last step in the development of the XDR phenotype involved various extended-spectrum beta-lactamase genes (bla
MeSH term(s)	Humans ; Anti-Bacterial Agents/pharmacology ; Anti-Bacterial Agents/therapeutic use ; Azithromycin/pharmacology ; Azithromycin/therapeutic use ; beta-Lactamases/genetics ; Ciprofloxacin/pharmacology ; Dysentery, Bacillary/drug therapy ; Dysentery, Bacillary/epidemiology ; France/epidemiology ; Microbial Sensitivity Tests ; Plasmids/genetics ; Shigella sonnei/drug effects ; Shigella sonnei/genetics ; Drug Resistance, Multiple, Bacterial
Chemical Substances	Anti-Bacterial Agents ; Azithromycin (83905-01-5) ; beta-Lactamases (EC 3.5.2.6) ; Ciprofloxacin (5E8K9I0O4U)
Language	English
Publishing date	2023-01-28
Publishing country	England
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	2553671-0
ISSN	2041-1723 ; 2041-1723
ISSN (online)	2041-1723
ISSN	2041-1723
DOI	10.1038/s41467-023-36222-8
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Rapid emergence of extensively drug-resistant Shigella sonnei in France

Sophie Lefèvre / Elisabeth Njamkepo / Sarah Feldman / Corinne Ruckly / Isabelle Carle / Monique Lejay-Collin / Laëtitia Fabre / Iman Yassine / Lise Frézal / Maria Pardos de la Gandara / Arnaud Fontanet / François-Xavier Weill

Nature Communications, Vol 14, Iss 1, Pp 1-

2023 Volume 10

Abstract: There have been increasing reports of extensively drug-resistant (XDR) Shigella sonnei infections in recent years. In this laboratory surveillance study from France, the authors document the rise of XDR isolates from 2005 to 2021 and perform whole genome ...

Abstract	There have been increasing reports of extensively drug-resistant (XDR) Shigella sonnei infections in recent years. In this laboratory surveillance study from France, the authors document the rise of XDR isolates from 2005 to 2021 and perform whole genome sequencing to investigate their genomic diversity and evolutionary history.
Keywords	Science ; Q
Language	English
Publishing date	2023-01-01T00:00:00Z
Publisher	Nature Portfolio
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Population structure analysis and laboratory monitoring of Shigella by core-genome multilocus sequence typing.

Yassine, Iman / Lefèvre, Sophie / Hansen, Elisabeth E / Ruckly, Corinne / Carle, Isabelle / Lejay-Collin, Monique / Fabre, Laëtitia / Rafei, Rayane / Clermont, Dominique / de la Gandara, Maria Pardos / Dabboussi, Fouad / Thomson, Nicholas R / Weill, François-Xavier

Nature communications

2022 Volume 13, Issue 1, Page(s) 551

Abstract: The laboratory surveillance of bacillary dysentery is based on a standardised Shigella typing scheme that classifies Shigella strains into four serogroups and more than 50 serotypes on the basis of biochemical tests and lipopolysaccharide O-antigen ... ...

Abstract	The laboratory surveillance of bacillary dysentery is based on a standardised Shigella typing scheme that classifies Shigella strains into four serogroups and more than 50 serotypes on the basis of biochemical tests and lipopolysaccharide O-antigen serotyping. Real-time genomic surveillance of Shigella infections has been implemented in several countries, but without the use of a standardised typing scheme. Here, we study over 4000 reference strains and clinical isolates of Shigella, covering all serotypes, with both the current serotyping scheme and the standardised EnteroBase core-genome multilocus sequence typing scheme (cgMLST). The Shigella genomes are grouped into eight phylogenetically distinct clusters, within the E. coli species. The cgMLST hierarchical clustering (HC) analysis at different levels of resolution (HC2000 to HC400) recognises the natural population structure of Shigella. By contrast, the serotyping scheme is affected by horizontal gene transfer, leading to a conflation of genetically unrelated Shigella strains and a separation of genetically related strains. The use of this cgMLST scheme will facilitate the transition from traditional phenotypic typing to routine whole-genome sequencing for the laboratory surveillance of Shigella infections.
MeSH term(s)	Disease Outbreaks ; Escherichia coli ; Genome, Bacterial ; Genotype ; Humans ; Molecular Epidemiology ; Multigene Family ; Multilocus Sequence Typing/methods ; Phylogeny ; Shigella/classification ; Shigella/genetics ; Shigella/isolation & purification ; Whole Genome Sequencing
Language	English
Publishing date	2022-01-27
Publishing country	England
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	2553671-0
ISSN	2041-1723 ; 2041-1723
ISSN (online)	2041-1723
ISSN	2041-1723
DOI	10.1038/s41467-022-28121-1
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Setting-Up a Rapid SARS-CoV-2 Genome Assessment by Next-Generation Sequencing in an Academic Hospital Center (LPCE, Louis Pasteur Hospital, Nice, France).

Frontiers in medicine

2022 Volume 8, Page(s) 730577

Abstract: Introduction: ...

Abstract	Introduction:
Language	English
Publishing date	2022-01-11
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2775999-4
ISSN	2296-858X
ISSN	2296-858X
DOI	10.3389/fmed.2021.730577
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

Order via subito

Details ▾
- Full text online
- Order with fees

Article ; Online: Characterization of lung cancers in patients with BRCA germline variants: A multicenter series.

Sanchis-Borja, Mateo / Fallet, Vincent / Fabre, Elisabeth / Wislez, Marie / Culine, Stéphane / Zalcman, Gérard / Spano, Jean-Philippe / Buffet, Nathalie Chabbert / Coulet, Florence / Benusiglio, Patrick R / Cadranel, Jacques

Lung cancer (Amsterdam, Netherlands)

2022 Volume 173, Page(s) 67–70

Abstract: Introduction: BRCA1 and BRCA2 (BReast CAncer susceptibility genes) are two tumor-suppressor genes associated with the hereditary breast and ovarian cancer susceptibility syndrome. Recent studies also suggest an increased lung adenocarcinoma risk in ... ...

Abstract	Introduction: BRCA1 and BRCA2 (BReast CAncer susceptibility genes) are two tumor-suppressor genes associated with the hereditary breast and ovarian cancer susceptibility syndrome. Recent studies also suggest an increased lung adenocarcinoma risk in carriers. Methods: We conducted a multi-center retrospective study in 18 different French pulmonology and/or oncology departments on medico-administrative and clinical data prospectively collected in the Clinical Data Warehouse (CDW) of Greater Paris University Hospitals (Assistance Publique-Hôpitaux de Paris, AP-HP). Clinical characteristics and outcomes of patients with LC and a previously known BRCA1/2gl variant were retrospectively evaluated. Results: 17 patients with LC and known BRCA1/2gl variant were included. Patients were most women, former smokers with localized disease and BRCA2 variants. All LC were adenocarcinoma. For patients with medical history of cancer, median time from the first cancer in the BRCA spectrum and the LC occurrence was 20 years. Median disease-free survival (DFS) and overall survival (OS) in localized tumor (Stage I and II) was not reached and 78.6 months, respectively. In advanced cancer (Stade III and IV) median progression free survival was 9.7 months and median OS was 17.8 months. Univariate OS and DFS/PFS analyses by BRCA status did not find significant differences. Conclusion: Results seem to show particular LC features in carriers of BRCA2 variants: adenocarcinoma subtype, woman, former or non-smoker.
MeSH term(s)	Female ; Humans ; Adenocarcinoma/genetics ; BRCA1 Protein/genetics ; Genes, BRCA2 ; Germ Cells/pathology ; Germ-Line Mutation ; Lung Neoplasms/genetics ; Retrospective Studies
Chemical Substances	BRCA1 Protein ; BRCA1 protein, human ; BRCA2 protein, human
Language	English
Publishing date	2022-09-06
Publishing country	Ireland
Document type	Multicenter Study ; Journal Article
ZDB-ID	632771-0
ISSN	1872-8332 ; 0169-5002
ISSN (online)	1872-8332
ISSN	0169-5002
DOI	10.1016/j.lungcan.2022.09.002
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 2135: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 423: Show issues

Order via subito

Details ▾

Article ; Online: Mapping for the management of diffuse pollution risks related to agricultural plant protection practices: case of the Etang de l'Or catchment area in France.

Mghirbi, Oussama / Bord, Jean-Paul / Le Grusse, Philippe / Mandart, Elisabeth / Fabre, Jacques

Environmental science and pollution research international

2018 Volume 25, Issue 14, Page(s) 14117–14137

Abstract: Faced with health, environmental, and socio-economic issues related to the heavy use of pesticides, diffuse phytosanitary pollution becomes a major concern shared by all the field actors. These actors, namely the farmers and territorial managers, have ... ...

Abstract	Faced with health, environmental, and socio-economic issues related to the heavy use of pesticides, diffuse phytosanitary pollution becomes a major concern shared by all the field actors. These actors, namely the farmers and territorial managers, have expressed the need to implement decision support tools for the territorial management of diffuse pollution resulting from the plant protection practices and their impacts. To meet these steadily increasing requests, a cartographic analysis approach was implemented based on GIS which allows the spatialization of the diffuse pollution impacts related to plant protection practices on the Etang de l'Or catchment area in the South of France. Risk mapping represents a support-decision tool that enables the different field actors to identify and locate vulnerable areas, so as to determine action plans and agri-environmental measures depending on the context of the natural environment. This work shows that mapping is helpful for managing risks related to the use of pesticides in agriculture by employing indicators of pressure (TFI) and risk on the applicator's health (IRSA) and on the environment (IRTE). These indicators were designed to assess the impact of plant protection practices at various spatial scales (field, farm, etc.). The cartographic analysis of risks related to plant protection practices shows that diffuse pollution is unequally located in the North (known for its abundant garrigues and vineyards) and in the South of the Etang de l'Or catchment area (the Mauguio-Lunel agricultural plain known for its diversified cropping systems). This spatial inequity is essentially related to land use and agricultural production system. Indeed, the agricultural lands cover about 60% of the total catchment area. Consequently, this cartographic analysis helps the territorial actors with the implementation of strategies for managing risks of diffuse pollution related to pesticides use in agriculture, based on environmental and socio-economic issues and the characteristics of the natural environment.
MeSH term(s)	Agriculture/methods ; Catchment Area (Health) ; Environmental Monitoring/methods ; Environmental Pollution/analysis ; Environmental Pollution/prevention & control ; France ; Pesticides/analysis ; Risk Management/methods ; Spatial Analysis
Chemical Substances	Pesticides
Language	English
Publishing date	2018-03-08
Publishing country	Germany
Document type	Journal Article
ZDB-ID	1178791-0
ISSN	1614-7499 ; 0944-1344
ISSN (online)	1614-7499
ISSN	0944-1344
DOI	10.1007/s11356-018-1556-7
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Bonn / Germany

Z 5915: Show issues

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Details ▾

Article ; Online: Phase I/Ib, open-label, multicenter, dose-escalation study of the anti-TGF-β monoclonal antibody, NIS793, in combination with spartalizumab in adult patients with advanced tumors.

Bauer, Todd M / Santoro, Armando / Lin, Chia-Chi / Garrido-Laguna, Ignacio / Joerger, Markus / Greil, Richard / Spreafico, Anna / Yau, Thomas / Goebeler, Maria-Elisabeth / Hütter-Krönke, Marie Luise / Perotti, Antonella / Juif, Pierre-Eric / Lu, Darlene / Barys, Louise / Cremasco, Viviana / Pelletier, Marc / Evans, Helen / Fabre, Claire / Doi, Toshikiko

Journal for immunotherapy of cancer

2023 Volume 11, Issue 11

Abstract: Background: NIS793 is a human IgG2 monoclonal antibody that binds to transforming growth factor beta (TGF-β). This first-in-human study investigated NIS793 plus spartalizumab treatment in patients with advanced solid tumors.: Methods: Patients ... ...

Abstract	Background: NIS793 is a human IgG2 monoclonal antibody that binds to transforming growth factor beta (TGF-β). This first-in-human study investigated NIS793 plus spartalizumab treatment in patients with advanced solid tumors. Methods: Patients received NIS793 (0.3-1 mg/kg every 3 weeks (Q3W)) monotherapy; following evaluation of two dose levels, dose escalation continued with NIS793 plus spartalizumab (NIS793 0.3-30 mg/kg Q3W and spartalizumab 300 mg Q3W or NIS793 20-30 mg/kg every 2 weeks [Q2W] and spartalizumab 400 mg every 4 weeks (Q4W)). In dose expansion, patients with non-small cell lung cancer (NSCLC) resistant to prior anti-programmed death ligand 1 or patients with microsatellite stable colorectal cancer (MSS-CRC) were treated at the recommended dose for expansion (RDE). Results: Sixty patients were treated in dose escalation, 11 with NIS793 monotherapy and 49 with NIS793 plus spartalizumab, and 60 patients were treated in dose expansion (MSS-CRC: n=40; NSCLC: n=20). No dose-limiting toxicities were observed. The RDE was established as NIS793 30 mg/kg (2100 mg) and spartalizumab 300 mg Q3W. Overall 54 (49.5%) patients experienced ≥1 treatment-related adverse event, most commonly rash (n=16; 13.3%), pruritus (n=10; 8.3%), and fatigue (n=9; 7.5%). Three partial responses were reported: one in renal cell carcinoma (NIS793 30 mg/kg Q2W plus spartalizumab 400 mg Q4W), and two in the MSS-CRC expansion cohort. Biomarker data showed evidence of target engagement through increased TGF-β/NIS793 complexes and depleted active TGF-β in peripheral blood. Gene expression analyses in tumor biopsies demonstrated decreased TGF-β target genes and signatures and increased immune signatures. Conclusions: In patients with advanced solid tumors, proof of mechanism of NIS793 is supported by evidence of target engagement and TGF-β pathway inhibition. Trial registration number: NCT02947165.
MeSH term(s)	Adult ; Humans ; Antibodies, Monoclonal/adverse effects ; Antineoplastic Agents/therapeutic use ; Carcinoma, Non-Small-Cell Lung/drug therapy ; Kidney Neoplasms/drug therapy ; Lung Neoplasms/drug therapy ; Transforming Growth Factor beta
Chemical Substances	Antibodies, Monoclonal ; Antineoplastic Agents ; NIS-793 ; spartalizumab (QOG25L6Z8Z) ; Transforming Growth Factor beta
Language	English
Publishing date	2023-11-29
Publishing country	England
Document type	Clinical Trial, Phase I ; Clinical Trial, Phase II ; Journal Article ; Multicenter Study ; Research Support, Non-U.S. Gov't
ZDB-ID	2719863-7
ISSN	2051-1426 ; 2051-1426
ISSN (online)	2051-1426
ISSN	2051-1426
DOI	10.1136/jitc-2023-007353
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

To top

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Bonn / Germany

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

Order via subito